Crinos Industria Farmacobiologica S.p.a.

Ennio Lanzarotti

Armando Cedro

Benito Casu

Roberto Porta

Laura Ferro

Giuseppe Prino

Giangiacomo Torri

Annamaria Naggi

Marisa Mantovani

Danilo Moltrasio

Fabio Trento

Cedro Armando

Franco Cattaneo

Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity. Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.

Fucans with low molecular weight having anticoagulant, antithrombinic

A pharmaceutical composition comprising a polydeoxyribonucleotide of random sequence formula is disclosed, and

Use of polydeoxyribonucleotides in diabetic neuropathies

The invention discloses new oligodeoxyribonucleotides of animal origin, having a molecular weight comprised between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The new compounds are endowed with a significant anti-ischemic activity.

Process producing lower molecular weight range oligodeoxyribonucleotides

There are provided oligodeoxyribonucleotides of animal origin, having a molecular weight between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The compounds are endowed with a significant anti-ischemic activity.

Treatment of cardiac ischemia by administration of a fraction of

Polysaccharides and more in particular glycosaminoglycans, their mixtures, fractions and derivatives thereof are effective agents in the therapy of acute peripheral neuropathies of traumatic and ischemic origin and in the therapy of acute peripheral neuropathies of toxic origin.

Use of polysaccharides in acute peripheral neuropathies

By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GMl) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GMl with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Process for the isolation and purification of monosialoganglioside from

By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GM1) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GM1 with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Growing community of inventors

Milan, Italy

Ennio Lanzarotti